They have a cancer drug discovery platform called EVade Ribonuclease, which targets the ribonucleic acid in cancer cells. Their products include Evade RNase QBI-139, a tumor growth inhibitor for various cancers, targeted EVade ribonucleases for tumor targeting therapy, and EVade ribonuclease zymogens that become active enzymes. Their technology allows for the engineering of human proteins for treating diseases. Quintessence Biosciences is currently conducting a Phase I clinical trial for their lead candidate, QBI-139, at renowned cancer centers.